Andrew Woolley
About Andrew Woolley
Andrew Woolley is a Principal Scientist at Bristol Myers Squibb, specializing in Tumor Microenvironment Translational Research in Redwood City, California.
Company
Andrew Woolley is currently employed at Bristol Myers Squibb. He serves as the Principal Scientist in the Tumor Microenvironment Translational Research IHC Group located in Redwood City, California, United States.
Title
Andrew Woolley holds the position of Principal Scientist in the Tumor Microenvironment Translational Research IHC Group at Bristol Myers Squibb. This role involves advanced research in immuno-oncology.
Previous Positions
Andrew Woolley has a rich professional background. He worked at AbbVie as Senior Scientist II - Translational Oncology from 2018 to 2021 in Redwood City, CA. At Symic Bio, he held two roles: Scientist II from 2016 to 2018 and Consultant Scientist (Preclinical Research) from 2015 to 2016, both in the San Francisco Bay Area. Before that, he was a Postdoctoral Research Associate at the University of New South Wales in Sydney, Australia from 2013 to 2015 and at Purdue University from 2011 to 2012 in West Lafayette, IN and Madison, WI. He also worked as a Graduate Research Assistant and Graduate Teaching Assistant at Purdue University from 2005 to 2011.
Education and Expertise
Andrew Woolley earned his Ph.D. in Neurobiology from Purdue University, where he studied from 2005 to 2011. He also holds a Bachelor of Science in Biology with Minors in Psychology, Chemistry, and Business from Indiana University Bloomington, achieved between 2001 and 2005. His expertise includes developing and validating biological assays for mechanism-of-action studies and IND filings, advanced microscopy techniques, biomedical imaging, and digital pathology data analysis.
Research and Laboratory Skills
Andrew Woolley has extensive experience in handling lab animals and conducting aseptic surgeries on various species including mice, rats, rabbits, cats, and sheep. His technical skills include advanced light microscopy techniques like Confocal, Time-lapse fluorescence, In vivo 2-photon, and Light sheet microscopy. He is proficient in X-ray micro-CT and Magnetic Resonance Imaging for biomedical imaging. Additionally, he is skilled in using various histology equipment and quantitative analysis of digital pathology data.
Management and Contributions
In his current role, Andrew Woolley manages a small team focused on generating well-validated IHC assays for translational immuno-oncology research. He serves as a subject matter expert for transferring in-house IHC assay protocols to CROs for additional validation in CAP/CLIA labs. His work involves delivering advanced spatial-analysis results using techniques like chromogenic immunohistochemistry, multiplex immunofluorescence, in situ hybridization, and spatial transcriptomics.